Cargando…

The Role of Activation of PI3K/AKT/mTOR and RAF/MEK/ERK Pathways in Aggressive Pituitary Adenomas—New Potential Therapeutic Approach—A Systematic Review

Pituitary tumors (PT) are mostly benign, although occasionally they demonstrate aggressive behavior, invasion of surrounding tissues, rapid growth, resistance to conventional treatments, and multiple recurrences. The pathogenesis of PT is still not fully understood, and the factors responsible for i...

Descripción completa

Detalles Bibliográficos
Autores principales:	Derwich, Aleksandra, Sykutera, Monika, Bromińska, Barbara, Rubiś, Błażej, Ruchała, Marek, Sawicka-Gutaj, Nadia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10341524/ https://www.ncbi.nlm.nih.gov/pubmed/37446128 http://dx.doi.org/10.3390/ijms241310952

Ejemplares similares

Clinical Implications of mTOR Expression in Papillary Thyroid Cancer—A Systematic Review
por: Derwich, Aleksandra, et al.
Publicado: (2023)

Targeting the PI3K/AKT/mTOR and RAF/MEK/ERK pathways for cancer therapy
por: Li, Qingfang, et al.
Publicado: (2022)

Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Inhibitors: Rationale and Importance to Inhibiting These Pathways in Human Health
por: Chappell, William H., et al.
Publicado: (2011)

Mutations and Deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Cascades Which Alter Therapy Response
por: McCubrey, James A., et al.
Publicado: (2012)

Inhibition of the PI3K/AKT/mTOR pathway activates autophagy and compensatory Ras/Raf/MEK/ERK signalling in prostate cancer
por: Butler, Dominika E., et al.
Publicado: (2017)

Roles of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity to therapy-implications for cancer and aging
por: Steelman, Linda S., et al.
Publicado: (2011)

“RAF” neighborhood: Protein–protein interaction in the Raf/Mek/Erk pathway
por: Cseh, Botond, et al.
Publicado: (2014)

Clinical, Biochemical, and Sonographic Factors Influencing Performance of Parathormone Washout Measurement vs. (99m)Tc-MIBI Scintigraphy in the Preoperative Diagnostics of Parathyroid Adenomas
por: Szczepanek-Parulska, Ewelina, et al.
Publicado: (2023)

Growth Inhibitory Signaling of the Raf/MEK/ERK Pathway
por: Wu, Pui-Kei, et al.
Publicado: (2020)

Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Cascade Inhibitors: How Mutations Can Result in Therapy Resistance and How to Overcome Resistance
por: McCubrey, James A., et al.
Publicado: (2012)

Des-gamma-carboxy prothrombin antagonizes the effects of Sorafenib on human hepatocellular carcinoma through activation of the Raf/MEK/ERK and PI3K/Akt/mTOR signaling pathways
por: Cui, Shu-Xiang, et al.
Publicado: (2016)

Modulation of the Akt/Ras/Raf/MEK/ERK pathway by A(3) adenosine receptor
por: Merighi, Stefania, et al.
Publicado: (2006)

Serum Visfatin/NAMPT as a Potential Risk Predictor for Malignancy of Adrenal Tumors
por: Sawicka-Gutaj, Nadia, et al.
Publicado: (2022)

Polymorphisms in RAS/RAF/MEK/ERK Pathway Are Associated with Gastric Cancer
por: Gonzalez-Hormazabal, Patricio, et al.
Publicado: (2018)

Targeting Aberrant RAS/RAF/MEK/ERK Signaling for Cancer Therapy
por: Degirmenci, Ufuk, et al.
Publicado: (2020)

Dihydroartemisinin inhibits the Raf/ERK/MEK and PI3K/AKT pathways in glioma cells
por: Du, Wei, et al.
Publicado: (2021)

Does nesfatin-1 influence the hypothalamic–pituitary–gonadal axis in adult males with obstructive sleep apnoea?
por: Batura-Gabryel, Halina, et al.
Publicado: (2019)

PDCD6 cooperates with C-Raf to facilitate colorectal cancer progression via Raf/MEK/ERK activation
por: Wang, Xiaojuan, et al.
Publicado: (2020)

PLX8394, a RAF inhibitor, inhibits enterovirus 71 replication by blocking RAF/MEK/ERK signaling
por: Wu, Chengyuan, et al.
Publicado: (2023)

Pituitary Crooke Cell Adenoma: Two Cases of an Aggressive Pituitary Adenoma
por: Taiwo, Adeyinka, et al.
Publicado: (2023)

Synergistic anti-tumour activity of sorafenib in combination with pegylated resveratrol is mediated by Akt/mTOR/p70S6k-4EBP-1 and c-Raf7MEK/ERK signaling pathways
por: Wang, Ligang, et al.
Publicado: (2023)

SODD Promotes Lung Cancer Tumorigenesis by Activating the PDK1/AKT and RAF/MEK/ERK Signaling
por: Bao, Fan, et al.
Publicado: (2023)

Global view of the RAF-MEK-ERK module and its immediate downstream effectors
por: Santini, Cristina C., et al.
Publicado: (2019)

Porcine deltacoronavirus activates the Raf/MEK/ERK pathway to promote its replication
por: Jeon, Ji Hyun, et al.
Publicado: (2020)

Reusability and composability in process description maps: RAS–RAF–MEK–ERK signalling
por: Mazein, Alexander, et al.
Publicado: (2021)

Direct Targeting of the Raf-MEK-ERK Signaling Cascade Inhibits Neuroblastoma Growth
por: Chilamakuri, Rameswari, et al.
Publicado: (2022)

Is eNAMPT/visfatin a potential serum marker of papillary thyroid cancer?
por: Sawicka-Gutaj, Nadia, et al.
Publicado: (2022)

Tanshinone IIA induces autophagy in colon cancer cells through MEK/ERK/mTOR pathway
por: Qian, Jun, et al.
Publicado: (2020)

Surgical treatment of aggressive pituitary adenomas and pituitary carcinomas
por: Buchfelder, Michael, et al.
Publicado: (2020)

RAS/RAF/MEK/ERK and PI3K/PTEN/AKT Signaling in Malignant Melanoma Progression and Therapy
por: Yajima, Ichiro, et al.
Publicado: (2012)

Temozolomide in aggressive pituitary adenomas and carcinomas
por: Ortiz, Leon D., et al.
Publicado: (2012)

Combination Therapies to Inhibit the RAF/MEK/ERK Pathway in Melanoma: We are not Done Yet
por: McArthur, Grant A.
Publicado: (2015)

The Ras/Raf/MEK/ERK signaling pathway and its role in the occurrence and development of HCC
por: Li, Lei, et al.
Publicado: (2016)

RDM1 promotes neuroblastoma growth through the RAS–Raf–MEK–ERK pathway
por: Xie, Guojin, et al.
Publicado: (2019)

Onco-immunomodulatory properties of pharmacological interference with RAS-RAF-MEK-ERK pathway hyperactivation
por: Avery, Thomas Yul, et al.
Publicado: (2022)

mTOR inhibition reduces cellular proliferation and sensitizes pituitary adenoma cells to ionizing radiation
por: Sukumari-Ramesh, Sangeetha, et al.
Publicado: (2011)

PDCD10 promotes the aggressive behaviors of pituitary adenomas by up-regulating CXCR2 and activating downstream AKT/ERK signaling
por: Liu, Jingdian, et al.
Publicado: (2022)

Incidence of pituitary autoantibodies in idiopathic diabetes insipidus
por: Gut, Paweł, et al.
Publicado: (2018)

Norcantharidin induces growth inhibition and apoptosis of glioma cells by blocking the Raf/MEK/ERK pathway
por: Zheng, Jie, et al.
Publicado: (2014)

Molecular signaling in multiple myeloma: association of RAS/RAF mutations and MEK/ERK pathway activation
por: Xu, J, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_ssif9i6a7knafgcnifil6om046